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The aim of this study was to determine the in vitro susceptibility of 170 clinical isolates of Mycobacterium
tuberculosis to fusidic acid using a proportion dilution method. Nineteen isolates were resistant to at least one
first-line anti-tuberculosis drug. A total of 1.8% of the isolates were resistant to fusidic acid. Fusidic acid should
be evaluated clinically as a potential supplementary drug for the treatment of infections due to multidrug-
resistant strains of M. tuberculosis.
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INTRODUCTION
Recently, tuberculosis (TB) has shown a rapid world-wide
spread. The incidence of resistant Mycobacterium tuberculosis to
single or multiple drug therapies employing standard drugs is
increasing in almost all industrialized and developing countries
[1,2]. Thus, TB treatment and the occurrence of multidrug-
resistant tuberculosis (MDRTB) have led to pressure for the rapid
development of new anti-tuberculosis drugs. Although the new
fluoroquinolones, and especially ofloxacin, b-lactam antibiotics
and fusidic acid, have been shown to be possible alternative
candidates, the development of resistance during treatment with
these drugs has been observed [3,4]. It has been shown that
fusidic acid has an inhibitory effect on strains of M. tuberculosis at
clinically relevant concentrations, and could therefore be used as
an alternative drug in infections with MDRTB [1,4].
The aim of this study was to determine the in vitro suscept-
ibility of local strains of M. tuberculosis to fusidic acid using a
proportion dilution method.
MATERIALS AND METHODS
One hundred and seventy clinical isolates of M. tuberculosis were
used in this study. All strains were isolated by culturing on
Lo¨wenstein–Jensen slants and by use of the MB/BacT (Orga-
non–Teknika) automated system. Organisms were identified to
species levels by standard methods [5]. M. tuberculosis strains
ATCC 27294, ATCC 35838, ATCC 35825 were used for
internal quality control.
Standard laboratory powders with known potency were
used. Isoniazid (INH), rifampin (RIF), etambutol (ETB) and
streptomycin (STR) were obtained from Sigma Chemical
Company (St Louis, MO, USA). The following drugs and
concentrations were included in agar proportion susceptibility
tests: INH 0.2 and 1 mg/L, RIF 1 mg/L, ETB 5 mg/L, STR
2 mg/L. Agar dilution testing was performed according to the
proportion dilution method as described in NCCLS tentative
standard M24-T and CDC recommendation [5,6]. Middleb-
rook 7H10 agar (Difco, Detroit, MI, USA) supplemented
with oleicacid-albumin-dextrose-catalase (OADC) enrichment
(BBL Microbiology Systems, Cockeysville, MD, USA) was
used. Colonies from a Lo¨wenstein–Jensen tube were homo-
genized in phosphate-buffered saline (pH 7.0) to achieve tur-
bidity equal to a McFarland 1.0 standard, corresponding to
approximately 109 colony-forming units per mL. The plates
were inoculated by spotting 100ml from a 102 and 104
dilution of a McFarland 1.0 in three spots on each quadrant,
then they were incubated at 37 8C in 5% CO2 for 3 weeks. In
the agar proportion dilution methods, an isolate was classified as
susceptible to a drug if the number of colonies that grew on the
drug-containing plate was <1% of the number of colonies that
grew on a control plate without drug, and resistant if the
number was 1% [5,6].
One hundred and fifty-one strains were susceptible to STR,
INH, RIF and ETB. Nineteen isolates were first-line resistant
drugs: 12 to INH, two to RIF, one to STR, and four to two
drugs, that is, one isolate was resistant both to STR and INH
and three isolates were resistant both to ETB and INH.
The values for maximum achievable concentration of fusidic
acid in serum vary in the literature [1,4,7]. Based on this, the
following minimum inhibitory concentrations (MIC; mg/L)
were chosen as the breakpoint for susceptibility. The breakpoint
of fusidic acid was 16 mg/L in the proportion dilution method.
Stock solutions of the agents were prepared on the day of testing
according to the recommendations of the manufacturers. The
standard proportion dilution method for M. tuberculosis, with a
single breakpoint concentration, was extend to four concentra-
tions, and the MIC range 16–256 mg/L was used.
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RESULTS
Three of 170 M. tuberculosis isolates (1.8%) were resistant to
fusidic acid. One hundred and fifty-one strains were found to be
susceptible to all conventional anti-tuberculosis drugs, and three
of these were resistant to fusidic acid. All of the remaining 19
isolates that were resistant to one or more conventional anti-
tuberculosis drugs were susceptible to fusidic acid. The MIC50
and MIC90 of fusidic acid were detected as16 mg/L (Table 1).
According to the achievable serum level (28.7 7.1 mg/L),
detected in a previous study, strains were classified as susceptible
and resistant [7]. MICs of three strains which were resistant to
fusidic acid were detected for 2–128 and 1–256 mg/L. No
cross-resistance was found between first-line drugs and fusidic
acid.
DISCUSSION
The activity of fusidic acid against 170 strains of M. tuberculosis
was evaluated in this study. In previous studies, fusidic acid with
a terminal serum elimination half-life had been detected after
5 h and the maximum serum concentration was 28.7 7.1 mg/
L following the standard oral dose of 500 mg sodium fusidate
[7]. Very few data are available on the in vivo and in vitro
susceptibility of M. tuberculosis to fusidic acid. In one of the
previous three studies, the in vitro agar proportion method was
used, 64 strains of M. tuberculosis were tested and 16 mg/L of
fusidic acid was found [4]. In the other two studies, the
BACTEC radiometric susceptibility method was used. In
one (comprising 40 M. tuberculosis strains, 20 of them resistant
to first-line drugs) the MIC50 and MIC90 were 16 mg/L. In the
other study (of 30 M. tuberculosis strains, 11 of them resistant to
first-line drugs) the activity of fusidic acid was under 32 mg/L,
except three strains in which it was 64 mg/L. Based on these
literature data, the breakpoint of fusidic acid used was 16 mg/L
and MIC50 and MIC90 were detected as 16 mg/L. By the use of
the agar proportion dilution method single breakpoints of the
drug were tested, thus MIC was extended fourfold and the MIC
range used was 16–256 mg/L. The MIC value of three of the
170 strains was detected as 128 mg/L for two of them and
256 mg/L for the other. This is based on previous data in which
they were accepted as resistant. In the previous studies there
were no data on the resistant strains that were isolated from three
patients, as to whether they had used any fusidic acid for another
infectious illness.
No differences in fusidic acid activity have been seen in
strains that are susceptible and resistant to first-line drugs. Also,
in three of the strains susceptible to first-line drugs resistance to
fusidic acid has been detected. Cross-resistance between first-
line drugs and fusidic acid has not been observed. Similar results
were also found in other studies [1,8].
During bacterial multiplication, resistance to anti-tuber-
culosis drugs develops spontaneously and with a defined
frequency. Genetic mutations resulting in resistance of M.
tuberculosis to RIF occur at a rate of 1010 per cell division
and lead to an estimated prevalence of one in 108 bacilli in drug-
free environments; the rate for INH is approximately
107109, resulting in resistance in one out of 106 bacilli.
Bacterial populations larger than 107 are common in cavities.
Thus, genetic resistance occurs in the absence of antimicrobial
exposure, but is diluted by the majority of drug-susceptible
micro-organisms. The presence of antimicrobials provides the
selective pressure for resistant organisms to become predomi-
nant, especially in patients with a large load of bacilli, e.g. those
with extensive cavitary disease. Exposure to a single drug due to
irregular drug supply, inappropriate prescription, or poor
adherence to treatment suppresses the growth of susceptible
bacilli to that drug but permits the multiplication of drug-
resistant organisms [9]. Fusidic acid is known to develop
resistance during treatment when used alone against Staphylo-
coccus aureus infection. This is probably due to a single-step
mutation to high-level resistance to fusidic acid, at a mutation
frequency of 105 to 106. A similar but lower resistance
frequency was seen in the study by Fuursted et al. [1] in strains
of the M. tuberculosis complex, with a resistance frequency of
<1.7 108 at four times the MIC. Moreover, the selected
fusidic acid-resistant organisms had significantly longer genera-
tion times than their sensitive parent organisms. This has also
been observed in mycobacteria with other drugs as well as with
fusidic acid for S. aureus [1]. Because of the absence of clinical
use of fusidic acid and the very few studies on this subject, the
resistance mechanism is not yet known.
Table1 Number of strains ofM. tuberculosis inhibited by fusidic acid at breakpoint concentrations
Fusidic acid (mg/L)
No. of strains 16 32 64 128 256
Resistant to one or more than one of the first-line drugsa 19 19 ^ ^ ^ ^
Susceptible to all first-line drugs 151 148 ^ ^ 2 1
Total 170 167 ^ ^ 2 1
a Number of strains resistant to the first-line drugs: INH (12), RIF (2), STR (1), STRþ INH (1), ETBþINH (3).
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On the basis of this study, the in vitro effect of fusidic acid
on M. tuberculosis is good. There is no cross-resistance with
first-line drugs. It should be tried clinically, especially in those
subjects whose M. tuberculosis is resistant to first-line drugs.
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